GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Elixinol Wellness Ltd (ASX:EXL) » Definitions » EV-to-Revenue

Elixinol Wellness (ASX:EXL) EV-to-Revenue : 0.70 (As of May. 25, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Elixinol Wellness EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Elixinol Wellness's enterprise value is A$5.76 Mil. Elixinol Wellness's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was A$8.27 Mil. Therefore, Elixinol Wellness's EV-to-Revenue for today is 0.70.

The historical rank and industry rank for Elixinol Wellness's EV-to-Revenue or its related term are showing as below:

ASX:EXL' s EV-to-Revenue Range Over the Past 10 Years
Min: -0.79   Med: 0.51   Max: 14.32
Current: 0.69

During the past 6 years, the highest EV-to-Revenue of Elixinol Wellness was 14.32. The lowest was -0.79. And the median was 0.51.

ASX:EXL's EV-to-Revenue is ranked better than
87.11% of 1024 companies
in the Drug Manufacturers industry
Industry Median: 2.285 vs ASX:EXL: 0.69

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-25), Elixinol Wellness's stock price is A$0.004. Elixinol Wellness's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.01. Therefore, Elixinol Wellness's PS Ratio for today is 0.31.


Elixinol Wellness EV-to-Revenue Historical Data

The historical data trend for Elixinol Wellness's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elixinol Wellness EV-to-Revenue Chart

Elixinol Wellness Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial 2.29 1.98 1.37 0.80 0.99

Elixinol Wellness Semi-Annual Data
Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.37 - 0.80 - 0.99

Competitive Comparison of Elixinol Wellness's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Elixinol Wellness's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Elixinol Wellness's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Elixinol Wellness's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Elixinol Wellness's EV-to-Revenue falls into.



Elixinol Wellness EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Elixinol Wellness's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=5.758/8.269
=0.70

Elixinol Wellness's current Enterprise Value is A$5.76 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Elixinol Wellness's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was A$8.27 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Elixinol Wellness  (ASX:EXL) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Elixinol Wellness's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.004/0.013
=0.31

Elixinol Wellness's share price for today is A$0.004.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was A$0.01.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Elixinol Wellness EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Elixinol Wellness's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Elixinol Wellness (ASX:EXL) Business Description

Traded in Other Exchanges
Address
680 George Street, Level 12, Sydney, NSW, AUS, 2000
Elixinol Wellness Ltd is engaged in the hemp industry, innovating, marketing, and selling hemp-derived nutraceutical, cosmetic, and food products. It operates in the geographical segments of the Americas, Australia, Europe and other regions of which key revenue is derived from the Americas segment. The Americas segment includes the trading results of Elixinol LLC (Elixinol Americas) and its investments and joint ventures in the US through the manufacture and distribution of hemp-derived cannabidiol products.

Elixinol Wellness (ASX:EXL) Headlines

No Headlines